Blood Monitoring and Data Acquisition and Utilization in Patients With Type 2 Diabetes Treated With Insulin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Management of type 2 diabetes is an ongoing challenge for patients and their doctors. In order to prevent complications, patients need to monitor and control their blood sugar levels. In addition, they may need to have an ongoing communication with their doctor in order to modify treatment. In this study the investigators wish to compare the benefits of continuous glucose monitoring system (CGMS) to an internet-based glucose monitoring system (IBGMS). The investigators also want to determine whether the frequency of blood glucose testing affects blood glucose control and to see whether the benefits of CGMS and IBGMS are independent of testing frequency.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparing Internet Blood Glucose Monitoring System and Continuous Glucose Monitoring System

NCT01162694

Type 2 Diabetes Mellitus

SUSPENDED NA

Continuous Glucose Monitoring in Patients With Type 2 Diabetes

NCT00529815

Diabetes Mellitus Type 2

UNKNOWN PHASE4

Internet Monitoring vs Medication to Control Blood Sugar in Type 2 Diabetes

NCT02185755

Type 2 Diabetes Mellitus

COMPLETED NA

Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)

NCT03620357

Diabetes Mellitus, Type 2

COMPLETED NA

Examining The Role of CGM in T2DM

NCT01614262

DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this current study, the investigators wish to test several hypotheses: whether the frequency of SMBG is correlated with HbA1c, whether the knowledge that strips are being counted affects HbA1c, whether the reduction of HbA1c when using an IBGMS is independent of the frequency of testing, and whether there is a difference between IBGMS and CGMS in HbA1c reduction.

The investigators will recruit 100 patients with type 2 diabetes who satisfy the inclusion/exclusion criteria. For the first visit, the patients will be immediately randomized into four groups. One group will be testing 3 times a day (SMBG). The second group will be similar to the SMBG group except they will know that we are counting the frequency of testing (SMBG With Knowledge). The third group will use an IBGMS and the fourth group will use a CGMS. During the first visit, we will teach the patient how to use the programs and machinery for their group. All four groups will be asked to follow the protocol and to visit their doctor in 3 month intervals for 6 months along with completed laboratory blood test results.

For the SMBG and the SMBG With Knowledge group, each will be given a new meter and be asked to test 3 times a day. They will also be required to keep a diary of their SMBG levels. The difference between the two is that the SMBG With Knowledge group will know that we are counting strips. The SMBG group will believe that we are testing a new meter and will not know that the SMBG With Knowledge group exists. This deception is necessary to test the experimental effect of if the patient knows that we are counting the frequency of testing, does that affect the frequency that they are testing. The investigators will tell the SMBG group that we are testing the accuracy of a new meter and they should test 3 times a day.

For the CGMS and IBGMS group, they will also be counting the frequency of blood glucose testing to see whether the benefits from both are independent of the number of tests. Furthermore, we wish to compare the these two methods of blood glucose monitoring. Both groups will have to upload their data onto the internet and communicate with their doctor every 2 weeks using a secure online web site.

At the end of 3 and 6 months, we will collect the frequency of testing from each group to determine whether increased glycemic control correlates with increased testing. We will also collect their SMBG diaries to see whether the written data correlates with the data on their meter. The investigators will also be comparing a measure of their blood glucose levels for each group and determining the effectiveness of CGMS and IBGMS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Internet Intervention

The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.

Group Type ACTIVE_COMPARATOR

Remote Blood Glucose Monitoring

Intervention Type OTHER

The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.

Continuous Glucose Monitoring

The use of CGMS (Sensor, receiver, transmitter) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will send the data to their endocrinologist and receive feedback based on the uploaded glucose data.

Group Type ACTIVE_COMPARATOR

Continuous Glucose Monitoring

Intervention Type OTHER

The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.

SMBG

The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.

Group Type ACTIVE_COMPARATOR

SMBG

Intervention Type OTHER

The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.

SMBG With Knowledge

The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.

Group Type ACTIVE_COMPARATOR

SMBG With Knowledge

Intervention Type OTHER

The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Remote Blood Glucose Monitoring

The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.

Intervention Type OTHER

Continuous Glucose Monitoring

The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.

Intervention Type OTHER

SMBG

The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.

Intervention Type OTHER

SMBG With Knowledge

The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Internet Blood Glucose Monitoring System Sensors, CGMS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 diabetes patients being treated with insulin for at least 3 months HbA1c \> 7%
* 25 years of age
* Willingness to test blood glucose levels a minimum of 3 times daily
* Willingness to be trained on using the Continuous Glucose Monitoring System
* Willingness to be randomized
* Trained in self-blood glucose monitoring
* Internet Access on a Windows Personal Computer
* No prior use or training on CGMS in the past 6 months
* No prior use or training on IBGMS in the past 6 months

Exclusion Criteria

* Patient with medical conditions that may affect their study participation or - - results will be excluded.
* Patients with the potential to become pregnant
* Patients using medications known to influence control of diabetes (eg steroids systemic or inhaled)
* Liver disease (AST or ALT levels \> 2.5 times the reference level)
* Renal insufficient with a serum creatinine level \> 200 μmol/L

Minimum Eligible Age

25 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No